Veneno Technologies has entered into a business alliance with Molmir Inc., a company with strong expertise in identifying and refining drug discovery seeds originating from academia, to build a new commercialization model that ensures academic drug discovery does not end at the research stage.
As academia-originated ventures are becoming increasingly central players in drug discovery, Japan still faces significant challenges in translating academic research achievement into commercial outcomes. One of the main barriers is the lack of practical knowledge and hands-on experience required to advance drug discovery programs toward industrialization.
To address this issue, Veneno and Molmir will combine Veneno’s proprietary DRP drug discovery platform, Veneno Suite / the PERISS method, with Molmir’s molecular dynamics evaluation technologies and its network of universities and medical institutions across Japan. Together, the two companies will launch a new end-to-end drug discovery engine designed to turn promising academic research into viable therapeutic candidates.
Globally, many innovative medicines are now being created by venture companies originating from academia. In Japan as well, government support programs and university startup initiatives are being established. However, the knowledge and experience needed for drug discovery have not yet been transferred sufficiently from established companies to startups. As a result, the mechanisms needed to convert outstanding academic research into real drug discovery projects and sustainable industrial value remain underdeveloped.
Against this backdrop, Veneno and Molmir aim to realize a model of drug discovery that does not end with research by combining outstanding academic research seeds with industry-level drug discovery know-how and execution capabilities. This partnership is an initiative to build an end-to-end drug discovery engine that can uncover the therapeutic potential hidden in academia and connect it to pharmaceutical companies and investors in the form of actual drug candidates.We invite you to follow the efforts of both companies as they work to create a new Japan-originated ecosystem for academia-driven drug discovery.
